Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners.
Eight adenosine analogs, 3-deaza-adenosine (DZA), 3-deaza-(+/-)aristeromycin (DZAri), 2',3'-dideoxy-adenosine (ddAdo), 2',3'-dideoxy-3-deaza-adenosine (ddDZA), 2',3'-dideoxy-3-deaza-(+/-)aristeromycin (ddDZAri), 3-deaza-5'-(+/-)noraristeromycin (DZNAri), 3-deaza-neplanocin A (DZNep), and neplanocin A (NepA), were tested as inhibitors of human placenta S-adenosylhomocysteine (AdoHcy) hydrolase. The order of potency for the inhibition of human placental AdoHcy hydrolase was: DZNep approximately NepA >> DZAri approximately DZNAri > DZA >> ddAdo approximately ddDZA approximately ddDZAri. These same analogs were examined for their anti-HIV-1 activities measured by the reduction in p24 antigen produced by 3'-azido-3'-deoxythymidine (AZT)-sensitive HIV-1 isolates, A012 and A018, in phytohemagglutinin-stimulated peripheral blood mononuclear (PBMCs) cells. Interestingly, DZNAri and the 2',3'-dideoxy 3-deaza-nucleosides (ddAdo, ddDZAri, and ddDZA) were only marginal inhibitors of p24 antigen production in HIV-1 infected PBMC. DZNAri is unique because it is the only DZA analog with a deleted methylene group that precludes anabolic phosphorylation. In contrast, the other analogs were potent inhibitors of p24 antigen production by both HIV-1 isolates. Thus it was postulated that these nucleoside analogs could exert their antiviral effect via a combination of anabolically generated nucleotides (with the exception of DZNAri), which could inhibit reverse transcriptase or other viral enzymes, and the inhibition of viral or cellular methylation reactions. Additionally, QSAR-like models based on the molecular mechanics (MM) were developed to predict the order of potency of eight adenosine analogs for the inhibition of human AdoHcy hydrolase. In view of the potent antiviral activities of the DZA analogs, this approach provides a promising tool for designing and screening of more potent AdoHcy hydrolase inhibitors and antiviral agents.
Gordon
Richard K
RK
Walter Reed Army Institute of Research, Washington, USA. richard.gordon@na.amedd.army.mil
Ginalski
Krzysztof
K
Rudnicki
Witold R
WR
Rychlewski
Leszek
L
Pankaskie
Marvin C
MC
Bujnicki
Janusz M
JM
Chiang
Peter K
PK
D043383:Adenosylhomocysteinase; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016655:HIV Core Protein p24 / Q000032:analysis / Q000096:biosynthesis; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D006867:Hydrolases / Q000037:antagonists & inhibitors*; D020128:Inhibitory Concentration 50; D007700:Kinetics; D016399:Lymphoma, T-Cell / Q000378:metabolism; D008715:Methionine / Q000737:chemistry / Q000378:metabolism; D008745:Methylation / Q000187:drug effects; D008958:Models, Molecular; D010766:Phosphorylation; D010920:Placenta / Q000201:enzymology; D011485:Protein Binding; D012435:S-Adenosylhomocysteine / Q000737:chemistry / Q000378:metabolism; D013601:T-Lymphocytes / Q000378:metabolism; D013816:Thermodynamics; D014372:Tubercidin / Q000031:analogs & derivatives* / Q000494:pharmacology*
D019380:Anti-HIV Agents; D004791:Enzyme Inhibitors; D016655:HIV Core Protein p24; D012435:S-Adenosylhomocysteine; D008715:Methionine; D006867:Hydrolases; D043383:Adenosylhomocysteinase; D014372:Tubercidin